Mangoceuticals (NASDAQ:MGRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Mangoceuticals (NASDAQ:MGRX) to a sell rating in a report published on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mangoceuticals in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Mangoceuticals Trading Down 4.1%

Shares of NASDAQ MGRX opened at $0.40 on Friday. Mangoceuticals has a twelve month low of $0.16 and a twelve month high of $2.75. The company has a market capitalization of $6.79 million, a price-to-earnings ratio of -0.16 and a beta of 2.54. The firm has a 50-day moving average of $0.40 and a two-hundred day moving average of $0.90.

Mangoceuticals (NASDAQ:MGRX) last issued its quarterly earnings results on Wednesday, April 1st. The company reported $0.13 earnings per share for the quarter. Mangoceuticals had a negative net margin of 4,536.70% and a negative return on equity of 109.38%. The company had revenue of $0.09 million during the quarter.

Institutional Trading of Mangoceuticals

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in Mangoceuticals by 35.4% during the second quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock valued at $40,000 after buying an additional 6,928 shares in the last quarter. Virtu Financial LLC purchased a new stake in Mangoceuticals during the fourth quarter valued at about $25,000. Boothbay Fund Management LLC purchased a new stake in Mangoceuticals during the fourth quarter valued at about $28,000. Jane Street Group LLC purchased a new stake in Mangoceuticals during the fourth quarter valued at about $35,000. Finally, Ikarian Capital LLC purchased a new stake in Mangoceuticals during the fourth quarter valued at about $102,000. 56.72% of the stock is owned by hedge funds and other institutional investors.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.